Recent Updates
Recently added Catalysts

Lumbar Puncture, Blood Collection

Phase 1

Angelman Syndrome | Unknown | Other |Biogen Inc.|Last Updated: Jan 28, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment20
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04103333Angelman Syndrome (AS) Biomarker StudyEARLY_PHASE1 COMPLETED 20Dec 18, 2019Jan 2, 2022Jan 28, 20225 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Ubiquitin-Protein Ligase E3A (UBE3A) Protein Levels in Each Age Group
Baseline up to Day 33
UBE3A Protein Levels in Each Genotype Group
Baseline up to Day 33
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeDIAGNOSTIC
Treatment Arms
ArmTypeDescription
Angelman Syndrome: Group 1EXPERIMENTALParticipants aged 0-6 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
Angelman Syndrome: Group 2EXPERIMENTALParticipants aged 7-12 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
Angelman Syndrome: Group 3EXPERIMENTALParticipants aged 13-18 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
Angelman Syndrome: Group 4EXPERIMENTALParticipants aged 19-50 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
Dup15q Syndrome: Group 1EXPERIMENTALParticipants aged 0-6 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
Dup15q Syndrome: Group 2EXPERIMENTALParticipants aged 7-12 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
Dup15q Syndrome: Group 3EXPERIMENTALParticipants aged 13-18 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
Dup15q Syndrome: Group 4EXPERIMENTALParticipants aged 19-50 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.
Interventions
NameTypeDescription
Lumbar PuncturePROCEDUREAdministered as specified in the treatment arm.
Blood CollectionPROCEDUREAdministered as specified in the treatment arm.
Unlock Study Design Details
Eligibility Criteria
Age RangeN/A — 50 Years
SexALL
Healthy VolunteersNo
Study Sites5

Key Inclusion Criteria: * Ability of the participant's legally authorized representative (LAR) to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local privacy regula...

Countries:United States
Unlock Eligibility Criteria